Physician profile
John Reggie Thomas
NPI 1265637151
$9,831.06
in general payments reported to CMS, 2019-2025
33 companies · $3,582 in 2025
The $3,582 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $497 · 2021: $768 · 2022: $590 · 2023: $843 · 2024: $2,993 · 2025: $3,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,844 · Food and Beverage: $3,532 · Education: $42.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,843.55 |
| Food and Beverage | $3,531.68 |
| Education | $42.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,222.45 | 2019-2025 | Apollo Esg Nxt System, Overstitch Endoscopic Suturing System, Overstitch Nxt Endoscopic Suturing System |
| Janssen Biotech, INC. | $782.59 | 2020-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $665.09 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Novo Nordisk INC | $593.55 | 2021-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.82 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $337.94 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $267.75 | 2021-2023 | Stelara |
| Gilead Sciences, INC. | $186.03 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $173.25 | 2024 | |
| Genzyme Corporation | $168.46 | 2022-2025 | |
| Echosens North America, INC. | $123.64 | 2025 | Fibroscan |
| Intercept Pharmaceuticals, INC. | $91.45 | 2020-2025 | Ocaliva |
| Celgene Corporation | $82.28 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $78.08 | 2019-2023 | Dificid |
| Olympus America INC. | $70.27 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.56 | 2021-2024 | |
| Madrigal Pharmaceuticals | $65.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $62.37 | 2022-2024 | Dupixent |
| Corcept Therapeutics | $60.12 | 2025 | Korlym |
| Qol Medical, LLC | $53.26 | 2019-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $47.12 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $45.07 | 2019-2021 | |
| Lilly USA, LLC | $44.49 | 2023-2025 | Omvoh |
| Organon LLC | $31.75 | 2023-2024 | Renflexis |
| Janssen Pharmaceuticals, INC | $22.17 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $19.67 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $18.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.30 | 2021 | |
| Ardelyx, INC. | $17.50 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $16.06 | 2022 | |
| Apollo Endosurgery US INC | $14.74 | 2019 | |
| Amgen INC. | $14.15 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.